Arcutis Biotherapeutics (ARQT) vs Viking Therapeutics (VKTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Arcutis Biotherapeutics (ARQT) has outperformed Viking Therapeutics (VKTX) over the past year, losing 10.6% versus a loss of 27.7%. Over five years, VKTX leads with a +360.4% price change compared with +58.1% for ARQT. Arcutis Biotherapeutics is the larger company by market cap ($3.33 billion vs $3.16 billion), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARQT | VKTX |
|---|---|---|
| Share price | $26.36 | $24.77 |
| Market cap | $3.33B | $3.16B |
| 1-day change | -2.98% | -4.14% |
| YTD return | -9.23% | -29.59% |
| 1-year return | -10.61% | -27.70% |
| 5-year return | +58.13% | +360.41% |
| P/E ratio (TTM) | 119.82 | — |
| Forward P/E | 24.09 | — |
| EPS (TTM) | $0.22 | $-5.42 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $376.07M | $0 |
| Revenue growth (YoY) | +91.34% | — |
| Net income (latest FY) | $-16.14M | $-359.64M |
| Gross margin | 90.24% | — |
| Operating margin | -3.25% | — |
| Net margin | -4.29% | — |
| 52-week high | $34.80 | $43.10 |
| 52-week low | $19.30 | $23.82 |
| Distance from 52-week high | -24.25% | -42.53% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +53.19% | +284.82% |
| Average volume | 2.58M | 5.31M |
| Shares outstanding | 126.46M | 127.52M |
| Employees | 354 | 74 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ARQT has outperformed VKTX by 17.1 percentage points over the past year.
About Arcutis Biotherapeutics
ARQT stock →Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 354 employees
About Viking Therapeutics
VKTX stock →Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. Its lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Health Care · Biotechnology: Pharmaceutical Preparations · 74 employees
ARQT vs VKTX FAQ
Which is bigger, Arcutis Biotherapeutics or Viking Therapeutics?
Arcutis Biotherapeutics (ARQT) is larger, with a market capitalization of $3.33B compared with $3.16B for Viking Therapeutics (VKTX).
Which stock has performed better over the past year, ARQT or VKTX?
ARQT returned -10.61% over the past 12 months, compared with -27.70% for VKTX (price return, excluding dividends). Past performance does not predict future results.
Are Arcutis Biotherapeutics and Viking Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.